New drug combo aims to tame inflammation and fight pancreatic cancer
NCT ID NCT04926467
Summary
This study is testing if adding a drug called anakinra, which reduces inflammation, to standard chemotherapy can better control pancreatic cancer in patients who are candidates for surgery. The goal is to see if this combination helps shrink tumors before surgery, improves survival, and reduces pain. About 24 adults with pancreatic cancer that hasn't spread to distant organs will receive the drug combination before and after their operation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor University Medical Center, Charles A Sammons Cancer Center
RECRUITINGDallas, Texas, 75246, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.